UNSPSC 51402205: Buspirone hydrochloride

This classification denotes an anxiolytic with the molecular formula C21H31N5O2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 207LT9J9OC, chemically known as 1,1-cyclopentanediacetimide, n-(4-(4-(2-pyrimidinyl)-1-piperazinyl)butyl)-, hydrochloride but more generally known as buspirone hydrochloride, which bears US NIH Compound Identifier 36431. European Medicines Agency schedules Buspirone hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00906MIG.

UNSPSC 51402205 Buspirone hydrochloride is a Commodity code that nominally identifies a specific anxiolytic pharmaceutical agent, but recent state and local procurement activity under this code shows minimal direct correlation to buspirone itself. The most recent opportunities solicited through this taxonomy entry reflect broader pharmaceutical and medication supply procurement rather than buspirone as a discrete product line. State and local health agencies, including county health departments, state health commissions, and multistate cooperative purchasing consortia, issue solicitations tagged to this code when procuring generic pharmaceuticals, over-the-counter products, naloxone and drug deactivation systems, and direct-to-manufacturer prescription programs. The scope of work spans supply agreements for pharmaceuticals distributed through authorized wholesalers, bulk procurement of emergency medications, and value-based pharmacy benefit program arrangements negotiated outside traditional pharmacy benefit manager channels.

Recent opportunities include Seminole County, Florida's IFB for 1,900 units of naloxone and 800 safe drug deactivation systems annually (IFB60459723LAS, response due July 26, 2023); the Texas Health and Human Services Commission's RFI on direct-to-manufacturer prescription programs (HHS0017013, posted April 3, 2026); and the Minnesota Multistate Cooperative Purchasing Alliance's RFP for generic multi-source pharmaceuticals and OTC products distributed across state and local facilities in Minnesota and Oregon (S1070000015802, response due March 26, 2026). Activity is concentrated in Florida, Texas, and Minnesota, with multistate cooperative purchasing extending geographic reach through coordinated wholesaler networks. The Minnesota RFP emphasizes compliance with cGMP, DSCSA, and FDA requirements; negotiated net pricing and WAC-minus structures; and performance penalties for reporting or onboarding delays. No recent opportunities show direct solicitation of buspirone as a named line item, suggesting the code reflects categorical taxonomy application rather than specific pharmaceutical targeting.